Rapid, accurate diagnostics. Anywhere, anytime.
The Clip COVID-19 rapid antigen test is the most accurate FDA authorized point-of-care test on the market with 100% NPA/Specificity and 96.9% PPA/Sensitivity and automated API-connected result integrations.*
*Data Source: AdVeritasDx Test Database
We empower you with access to reliable, actionable health data, fast.
COVID-19 + Flu Test
15-minute Rx home use test
Detection and differentiation of SARS-CoV-2, influenza A, and influenza B antigens from a self-collected nasal swab. Readout using the re-usable Core analyzer connected to the Clip Health iOS/Android app.
*In late development, pending FDA EUA submission
COVID-19 Point-of-Care Test
30-minute point-of-care antigen test
EUA-authorized. Detection of SARS-CoV-2 nucleocapsid protein from anterior nose swab. Verified to detect the delta variant in symptomatic and asymptomatic individuals. Readout using Clip Analyzer, an iPhone-connected analyzer for high-volume point-of-care use.
Our product vision is to enable accessible, personalized, and actionable health testing, with immediate follow-up, across infectious, metabolic, endocrine, and chronic diseases and conditions.
Want to keep in touch?
Be the first to know about our products.
Sign up for updates on products, pre-orders, news & announcements, and all things Clip Health!
The Clip hardware and software leverage patented innovations in nanotechnology, materials chemistry, and signal processing to enable high-accuracy, cost-effective diagnostics.
Who we are
Clip Health is a health-tech company with a mission of increasing healthcare accessibility and efficiency by designing, developing, manufacturing, and delivering products and services that enable affordable, widespread access to actionable health testing with immediate follow-up.
Want to join the team? We’re hiring.
See all open positions
Emergency Use Authorization (EUA) Disclaimer
© 2021 Luminostics, Inc. dba Clip Health In the USA, the Clip COVID Rapid Antigen Test has not been FDA cleared or approved, but has been authorized by FDA under an EUA for emergency use by laboratories certified under the CLIA, 42 U.S.C. §263a, that meet the requirements to perform high, moderate, or waived complexity tests. This test is for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation. This test has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens. In the USA, the emergency use of this test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of the virus that causes COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.